CTLA4 and neoplasm: CTLA-4 can down-regulate or terminate T cell- mediated immune responses by inhibiting T cell activity, which is consistent with the notion that CTLA-4 is a negative regulator of the anti-tumor immune response, demonstrating that antibody blockade of CTLA-4 could result in antitumor immunity in preclinical models.